12 results about "Ischemic vascular dementia" patented technology

This invention discloses a compound preparation for treating vascular dementia and its preparation method. The active pharmaceutical ingredient consists of protopanaxadiol and gallic acid in a 1:1 mass ratio, and the dosage form is liposomes. The preparation method includes extraction, mixing, liposome preparation, and optional freeze-drying steps: protopanaxadiol and gallic acid are extracted and purified from ginseng rhizome and Terminalia chebula fruit, respectively. After mixing, they are combined with phospholipids and cholesterol to prepare a lipid membrane. The membrane is then homogenized by hydration, low-temperature ultrasound, and high-pressure microfluidic jet to obtain a homogeneous liposome suspension, which can be further freeze-dried into a freeze-dried powder. The 1:1 composition of protopanaxadiol and gallic acid targets multiple points on the pathological mechanism of vascular dementia, showing significant therapeutic effects and broad application prospects. This preparation uses a liposome dosage form to improve the bioavailability of the active ingredient, the preparation process parameters are controllable, the active ingredient has high purity, the liposomes have uniform particle size, high encapsulation efficiency, and good stability.

This invention discloses the application of total small molecules of Polygonatum cyrtonema in the preparation of drugs for treating vascular dementia, belonging to the field of natural medicine technology. This invention obtains total small molecules of Polygonatum cyrtonema through a combination of water extraction and alcohol precipitation with macroporous adsorption resin purification. Experiments using a rat model of vascular dementia showed that these total small molecules of Polygonatum cyrtonema effectively improved the degree of neurological function impairment and learning and memory abilities in rats, indicating that the total small molecules of Polygonatum cyrtonema prepared by this invention can effectively treat vascular dementia, providing a new drug source and treatment method for clinical vascular dementia treatment.

This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.

The application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating cognitive impairment and a preparation method thereof. The preparation method of the traditional Chinese medicine composition comprises the following steps: S1. adding modified mesoporous silicon dioxide to water extracts of ginseng, poria cocos, polygala, acorus gramineus, bupleurum, radix curcumae, cyperus rotundus and chuanxiong, grinding, vacuum drying, and preparing an intermediate product; and S2. mixing the intermediate product with microcrystalline cellulose, mannitol, sodium carboxymethyl starch and a stabilizer, adding a binder, extruding and rounding, drying, sieving, and preparing the traditional Chinese medicine composition. The method is simple in steps and easy to put into production. The obtained traditional Chinese medicine composition can significantly improve the oxidative stress damage of a vascular dementia model rat.

This invention discloses a class of 3-substituted phthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of drugs for the treatment and / or prevention of neurological diseases, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

The application discloses a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating anxiety symptoms and / or depression symptoms of a vascular dementia patient, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition in the application has the function of nourishing blood and tranquilizing the mind, and the medicine developed by combining the traditional Chinese medicine composition with a brain metabolism medicine component has obvious improvement effect on the treatment of anxiety symptoms and depression symptoms of the vascular dementia patient, can preferably improve the healthy qi to stabilize the mood, promote blood circulation to relieve the anxiety symptoms and depression symptoms of the vascular dementia patient, is beneficial to the improvement of the mental state of the patient, and will not cause harmful side effects.

The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.

This invention discloses a class of piperidine alkyl dihydroxyphthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of medicaments for treating and / or preventing diseases by means of anti-oxidative stress, inhibition of amyloid aggregation, metal ion complexation, or anti-neuroinflammatory effects, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

This invention provides a medicinal and edible homologous composition for improving vascular dementia, its preparation method, and its application. The composition comprises the following parts by weight of raw materials and fructooligosaccharides: 80-120 parts of steamed Polygonatum sibiricum, 50-70 parts of mulberry, 50-70 parts of wolfberry, 30-50 parts of Poria cocos, 30-50 parts of Astragalus membranaceus, 30-50 parts of donkey-hide gelatin, and 30-50 parts of Codonopsis pilosula; the weight ratio of fructooligosaccharides to the extract obtained from the raw materials is (1.5-3):1. The raw materials used in this invention are all medicinal and edible homologous substances, safe and non-toxic, and can be taken long-term as a functional food. After process optimization, it has a good taste, sweet but not greasy, and high patient compliance. Animal experiments have confirmed that it can significantly improve the learning and memory abilities of rats with vascular dementia. It has the advantages of simple formulation, stable process, definite efficacy, convenient administration, and wide applicability, and has important clinical significance and good market application prospects.

This invention discloses the application of Polygonatum odoratum carbon quantum dots (PC-CQDs) in the preparation of drugs for treating vascular dementia, belonging to the field of pharmaceutical technology. This invention is the first to apply PC-CQDs to the treatment of vascular dementia. Morris water maze test and hippocampal histopathological analysis confirmed that PC-CQDs can significantly improve spatial learning and memory abilities in VaD rats, protect hippocampal neurons, and exhibit good biocompatibility. This invention provides a new drug option for the treatment of vascular dementia, possessing significant clinical application value and broad market prospects.